Longeveron (NASDAQ:LGVN) Issues Quarterly Earnings Results, Meets Expectations

Longeveron (NASDAQ:LGVN) issued its quarterly earnings data on Wednesday. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19), FiscalAI reports. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.33 million. Longeveron had a negative return on equity of 199.79% and a negative net margin of 1,893.58%.

Here are the key takeaways from Longeveron’s conference call:

• Longeveron said it raised new capital from several life sciences investors and is shifting to a more capital-efficient, asset-light model that emphasizes partnering to maximize shareholder value.
• The company reiterated that the most important near-term catalyst is ELPIS II top-line data for HLHS, expected in August 2026, and it plans to engage the FDA quickly after the readout.
• After a recent Type C meeting, the FDA said the current primary endpoint in ELPIS II is not appropriate for demonstrating efficacy and no new primary endpoint can be agreed to while the trial is ongoing.
• Management remains optimistic that ELPIS II results, together with other evidence and a sponsor SAP, could still support a future BLA, and the FDA said it is willing to meet again once the study is complete.
• Cash and cash equivalents were $15.8 million at quarter-end, and the company said this should fund operations into Q4 2026 based on its current budget and forecast.

Longeveron Stock Up 0.7%

Shares of LGVN traded up $0.00 during midday trading on Wednesday, hitting $0.76. The stock had a trading volume of 439,066 shares, compared to its average volume of 3,894,041. The company has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $0.73. Longeveron has a twelve month low of $0.48 and a twelve month high of $1.80. The firm has a market cap of $17.57 million, a price-to-earnings ratio of -0.59 and a beta of -0.31. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.33 and a quick ratio of 1.33.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. XTX Topco Ltd bought a new stake in Longeveron Inc. (NASDAQ:LGVN) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned about 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on LGVN shares. HC Wainwright dropped their price objective on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, May 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Longeveron in a research note on Tuesday, April 21st. Maxim Group downgraded Longeveron from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Wall Street Zen downgraded Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.50.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.